Autoimmune necrotizing myopathy after statin discontinuation

Abid, Haisam; Watthanasuntorn, Kanramon; Bischof, Edward

doi:10.1136/bcr-2019-229656

Search citation statements

Order By: Relevance

Paper Sections

Select...

Figure 1: Proposed Pathogenesis Of Sinam1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2023

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IV immunoglobulin in a 70-year-old patient has been used to successfully treat a case of biopsy-proven SINAM after cessation of statin therapy [12]. In another case, a 55-year-old patient suffered a 7-month insidious course of muscle weakness, after 4 years of atorvastatin usage; medical management, in this case, included IV immune globulin, IV methylprednisolone, methotrexate, and folic acid [13].…”

Section: Figure 1: Proposed Pathogenesis Of Sinammentioning

confidence: 99%

Immune-Mediated Myopathy in a Patient Presenting for Melanoma Resection and Sentinel Lymph Node Biopsy

Escher¹,

Hoffman²,

Alfieri³

et al. 2022

Cureus

View full text Add to dashboard Cite

Statin-induced necrotizing autoimmune myopathy (SINAM) is a rare side effect in people who are taking a class of drugs called statins. Patients with SINAM will present with subacute severe symmetric proximal muscle weakness. In contrast to more common myopathies, SINAM may not spontaneously resolve with statin discontinuation. These patients may require long-term immunotherapy to limit further disease progression. In this case study, we report a 74-year-old female with SINAM who presented for radical excision of a right upper back melanoma and sentinel lymph node biopsy at an outpatient facility. An anesthetic plan was crafted with the use of a supraglottic airway device without neuromuscular blockade.

show abstract

Section: Figure 1: Proposed Pathogenesis Of Sinammentioning

confidence: 99%